SEC Company Response from Quadrant Biosciences Inc (CIK 0001651239) — Mar 5, 2020
Quadrant Biosciences Inc (CIK 0001651239)
Date: March 5, 2020 · CIK: 0001651239 · Accession: 0001104659-20-029644
AI Filing Summary & Sentiment
File numbers found in text: 024-11155
Letter
Office of Life Sciences Division of Corporate Finance United States Securities and Exchange Commission March 5, 2020 Offering Statement on Form 1-A File No. 024-11155
Re: Quadrant Biosciences Inc.
Dear Ms. Murphy,
On behalf of Quadrant Biosciences Inc., I hereby request qualification of the above-referenced offering statement at 4pm Eastern time March 9, 2020, or as soon thereafter as is practicable.
Sincerely,
/s/ Richard Uhlig
Show Raw Text
CORRESP
1
filename1.htm
Celeste Murphy, Legal Branch Chief
Office of Life Sciences
Division of Corporate Finance
United States Securities and Exchange Commission
Washington, D.C. 20549
March 5, 2020
Re:
Quadrant Biosciences Inc.
Offering Statement on Form 1-A
File No. 024-11155
Dear Ms. Murphy,
On behalf of Quadrant Biosciences Inc., I hereby request qualification
of the above-referenced offering statement at 4pm Eastern time March 9, 2020, or as soon thereafter as is practicable.
Sincerely,
/s/ Richard Uhlig
Richard Uhlig
Chief Executive Officer
Quadrant Biosciences Inc.